Table 1.
Demographic and clinical characteristics of the study patients (n = 320)
| Characteristics | Value |
|---|---|
| Age (years), mean ± SD | 69.67 ± 16.39 |
| Male, n (%) | 221 (69.06%) |
| Hospitalization days, mean ± SD | 24.57 ± 15.58 |
| Linezolid therapy duration, days, mean ± SD | 7.40 ± 5.75 |
| Creatinine clearance, mL/min | |
| ≥ 60 ml/min | 193 (60.3%) |
| ≥ 30, < 60 ml/min | 75 (23.4%) |
| < 30 ml/min | 52 (16.3%) |
| Baseline laboratory data, mean ± SD | |
| Total bilirubin (μmol/L) | 20.31 ± 49.81 |
| ALT (U/L) | 74.04 ± 173.2 |
| AST (U/L) | 85.37 ± 217.5 |
| Total protein (g/L) | 59.54 ± 9.66 |
| Serum albumin (g/L) | 31.6 ± 5.46 |
| Platelet count (109/L) | 240.47 ± 120.65 |
| Haemoglobin (g/L) | 109.32 ± 22.99 |
| Intensive care, n (%) | 168 (52.5%) |
| Shocka, n (%) | 107 (33.4%) |
| Comorbid diseases, n (%) | |
| Hypertension | 174 (54.4%) |
| Diabetes | 75 (23.4%) |
| Malignant tumor | 19 (5.9%) |
| Stroke | 93 (29.0%) |
| Cardiac insufficiency | 97 (30.3%) |
| Chronic lung disease | 25 (7.8%) |
| Concurrent medications, n (%) | |
| Aspirin | 45 (14.1%) |
| Clopidogrel | 38 (11.8%) |
| Low molecular weight heparins | 79 (24.7%) |
ALT alanine aminotransferase; AST glutamic oxaloacetic transaminase
aShock patients require vasoactive medications